Wan C Tan1, Jean Bourbeau2, Gilbert Nadeau3, Wendy Wang4, Neil Barnes5, Sarah H Landis6, Miranda Kirby4,7, James C Hogg4, Don D Sin4,8. 1. Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada wan.tan@hli.ubc.ca. 2. Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, McGill University, Montréal, QC, Canada. 3. Respiratory Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada. 4. Centre for Heart Lung Innovation, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. 5. William Harvey Institute, Bart's and the London School of Medicine and Dentistry, and Respiratory Therapy Area, GlaxoSmithKline plc, London, UK. 6. Real World Evidence and Epidemiology, GlaxoSmithKline plc, Uxbridge, UK. 7. Dept of Physics, Ryerson University, Toronto, ON, Canada. 8. A list of members of the COLD/CanCOLD Collaborative Research Group can be found in the acknowledgements section.
Abstract
INTRODUCTION: The aim of this study was to examine the association between blood eosinophil levels and the decline in lung function in individuals aged >40 years from the general population. METHODS: The study evaluated the eosinophil counts from thawed blood in 1120 participants (mean age 65 years) from the prospective population-based Canadian Cohort of Obstructive Lung Disease (CanCOLD) study. Participants answered interviewer-administered respiratory questionnaires and performed pre-/post-bronchodilator spirometric tests at 18-month intervals; computed tomography (CT) imaging was performed at baseline. Statistical analyses to describe the relationship between eosinophil levels and decline in forced expiratory volume in 1 s (FEV1) were performed using random mixed-effects regression models with adjustments for demographics, smoking, baseline FEV1, ever-asthma and history of exacerbations in the previous 12 months. CT measurements were compared between eosinophil subgroups using ANOVA. RESULTS: Participants who had a peripheral eosinophil count of ≥300 cells·µL-1 (n=273) had a greater decline in FEV1 compared with those with eosinophil counts of <150 cells·µL-1 (n=430; p=0.003) (reference group) and 150-<300 cells·µL-1 (n=417; p=0.003). The absolute change in FEV1 was -32.99 mL·year-1 for participants with eosinophil counts <150 cells·µL-1; -38.78 mL·year-1 for those with 150-<300 cells·µL-1 and -67.30 mL·year-1 for participants with ≥300 cells·µL-1. In COPD, higher eosinophil count was associated with quantitative CT measurements reflecting both small and large airway abnormalities. CONCLUSION: A blood eosinophil count of ≥300 cells·µL-1 is an independent risk factor for accelerated lung function decline in older adults and is related to undetected structural airway abnormalities.
INTRODUCTION: The aim of this study was to examine the association between blood eosinophil levels and the decline in lung function in individuals aged >40 years from the general population. METHODS: The study evaluated the eosinophil counts from thawed blood in 1120 participants (mean age 65 years) from the prospective population-based Canadian Cohort of Obstructive Lung Disease (CanCOLD) study. Participants answered interviewer-administered respiratory questionnaires and performed pre-/post-bronchodilator spirometric tests at 18-month intervals; computed tomography (CT) imaging was performed at baseline. Statistical analyses to describe the relationship between eosinophil levels and decline in forced expiratory volume in 1 s (FEV1) were performed using random mixed-effects regression models with adjustments for demographics, smoking, baseline FEV1, ever-asthma and history of exacerbations in the previous 12 months. CT measurements were compared between eosinophil subgroups using ANOVA. RESULTS:Participants who had a peripheral eosinophil count of ≥300 cells·µL-1 (n=273) had a greater decline in FEV1 compared with those with eosinophil counts of <150 cells·µL-1 (n=430; p=0.003) (reference group) and 150-<300 cells·µL-1 (n=417; p=0.003). The absolute change in FEV1 was -32.99 mL·year-1 for participants with eosinophil counts <150 cells·µL-1; -38.78 mL·year-1 for those with 150-<300 cells·µL-1 and -67.30 mL·year-1 for participants with ≥300 cells·µL-1. In COPD, higher eosinophil count was associated with quantitative CT measurements reflecting both small and large airway abnormalities. CONCLUSION: A blood eosinophil count of ≥300 cells·µL-1 is an independent risk factor for accelerated lung function decline in older adults and is related to undetected structural airway abnormalities.
Authors: Fernando Timoteo Fernandes; Tiago Almeida de Oliveira; Cristiane Esteves Teixeira; Andre Filipe de Moraes Batista; Gabriel Dalla Costa; Alexandre Dias Porto Chiavegatto Filho Journal: Sci Rep Date: 2021-02-08 Impact factor: 4.379
Authors: Marc Miravitlles; Juan José Soler-Cataluña; Joan B Soriano; Francisco García-Río; Pilar de Lucas; Inmaculada Alfageme; Ciro Casanova; José Miguel Rodríguez González-Moro; M Guadalupe Sánchez-Herrero; Julio Ancochea; Borja G Cosío Journal: Respir Res Date: 2022-03-05
Authors: Shiyang Ma; James Dalgleish; Justin Lee; Chen Wang; Linxi Liu; Richard Gill; Joseph D Buxbaum; Wendy K Chung; Hugues Aschard; Edwin K Silverman; Michael H Cho; Zihuai He; Iuliana Ionita-Laza Journal: Proc Natl Acad Sci U S A Date: 2021-11-23 Impact factor: 12.779